TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

NextPoint Therapeutics Commences Phase 1a/b Clinical Trial for NPX887, a Novel Treatment Targeting HHLA2 to Activate Exhausted T and NK Cells in HHLA2-Positive Solid Tumors

Wednesday, February 21, 2024

NextPoint Therapeutics, a biotechnology company in the clinical stage, has disclosed the dosing of the first patient with NPX887 in a Phase 1 clinical trial targeting solid tumors expressing HHLA2/B7-H7, a tumor antigen highly present in various cancers regardless of PD-L1 expression.

NextPoint Therapeutics, the trial, denoted as Phase 1a/1b and registered under NCT06240728, aims to assess NPX887's safety, pharmacokinetics, immunogenicity, and biomarker-guided patient selection.

NPX887, a fully human monoclonal antibody, seeks to counteract KIR3DL3-mediated immunosuppression by targeting HHLA2, thereby enhancing antitumor activity within the tumor microenvironment.

This initiative follows their prior clinical program, NPX267, which also targets HHLA2 through the KIR3DL3 receptor. Both programs aim to exploit HHLA2 as an independent checkpoint for tumor-immune response, distinct from PD-L1, with the aim of providing tailored therapies for patients most likely to benefit.

NPX887 holds promise as a monotherapy for selected patient populations, demonstrating NextPoint Therapeutics' dedication to advancing precision oncology treatments. For further information on the trial, please visit (NCT06240728).



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit